Amadeus Capital Partners

"The entire team is very excited about the opportunity that this financing has given us to develop Unlikely AI and its technology, and we are delighted to partner with our new investors."

"Previous attempts at contact center automation have been disappointing,"

"Our increasing desire for continually improving electronic device performance paired with the absolute necessity to reduce our power requirements, and hence carbon footprints, demands new technology solutions – next generation materials will be at the heart of this. At Paragraf we are proud to be leading the way, bringing the first 2D material, graphene, into the electronic product supply chain, through our first products, allowing its transformational, game changing properties and benefits to be harnessed."

"There’s a fundamental productivity problem in biotech today. A biotech scientist needs to know how to make proteins to design drugs. That’s like expecting a computer scientist to know how to build a computer to design software,"

"It will be used—but it will also be abused."

"Our mission as a company is to enable widespread patient access to life saving cell and gene therapies. One of the biggest obstacles to achieving this is cell and gene therapy manufacturing processes that are too expensive, too highly variable and too low throughput. Our team is focused on the urgent need to enhance the ability of cell and gene therapy developers, CDMOs and Academic Medical Centers to deliver these therapies to as many patients as possible as quickly as possible,"

"Organisations that can extract insights from big data in a timely manner will be the leaders of tomorrow. Our investment in Brytlyt.io is in firm support of that thesis. We are therefore delighted to welcome Brytlyt.io, and visionary founder Richard, into our growing portfolio of cutting-edge data companies that includes Quantexa, Solidatus, Elliptic and more"

"Today, we’ve developed the world’s first Engineering-Grade AR solution helping construction teams identify errors in real-time, but really that’s just the start of our journey. The next phase is Assisted Reality, where our spatial computing technology will have the intelligence to automatically detect and report issues in the field. And ultimately, the goal is builders building from holograms. Our vision of developing world changing products aligns with Octopus Ventures’ mission of investing in companies that are powering the next industrial revolution. We look forward to building history."

"Doctify co-founders Stephanie and Suman, both surgeons by background, bring deep expertise in healthcare and are in prime position to transform and win the market. Their solution is driving real-time improvements to patient care across multiple international providers."

"For a quantum ecosystem to thrive, we urgently need an operating system. An operating system makes quantum computers useful – it allows programs and applications to run on many different machines. Riverlane aims to make our operating system Deltaflow a global standard."

"The story of the last 5 years for AI-first companies has been one of rapidly evolving tooling and infrastructure best practices. The very best AI-first companies are now moving from their home-grown data annotation, versioning and model lifecycle management tools to V7’s SaaS platform because it abstracts this complexity and exposes industry best practices. Companies can now iterate faster and have confidence in the robustness of their production models by building on V7."

"There’s never been a greater need to effectively deploy ML models in enterprise, and this fresh capital injection will ensure our customers have the tools they need to achieve their goals."

"Video files are typically large in size and present unique challenges of scale and security for access, processing, review and supply compared to other data. Without specialist automation data security is impossible to manage at any scale. Our products are currently being used in the preparation of video evidence, the anonymisation of visual data for analytics and for compliance with GDPR and other data protection legislation."

"Closing a significant Series A round, during these uncertain times, further validates Ori’s disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality, and decrease costs,"

"Our aim is to enable the potential of quantum mechanics using quantum photonics hardware. This funding will allow us to do just that – a world-class multidisciplinary team and our new laboratories will give Nu Quantum the ability to deliver meaningful demonstrations of our technology into the hands of customers and partners for the first time."

"We have been very busy in the two years since our last funding round in 2018. Our approach to tackling fraud and risk for enterprise-scale businesses has resonated with the market and we’ve grown our client base rapidly"

"Even before the crisis, SLAMcore was engaged in many conversations with companies – big and small – who needed a better way to solve spatial intelligence issues in robotics. Especially across sectors such as drones, robots, and AR/VR, the coronavirus pandemic has lit the touch-paper and we are primed to meet exploding demand. In the past few weeks alone, we have seen a huge spike in enquiries as robotics companies want fast solutions to get their robots to market sooner."

"Amadeus Capital Partners has shown confidence in our future by backing us again,"

"The UK alone spends £3.1bn on treating chronic wounds each year, while the US spends $50bn. Add to this the significant escalation in costs, not to mention the considerable distress to patients and families if the only course of treatment for non-healing wounds is amputation. It’s clear that there’s a real need for innovation in this area."

"We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials."

"Hundreds of clinical trials and a few recently marketed products have shown the revolutionary potential of CGTs. But this potential will never be realised unless we can remove the current bottleneck around scalable manufacturing. Ori Biotech has developed an innovative platform technology to facilitate scalable manufacturing that could eventually enable millions of patients to get access to the next generation of personalised medicines,"

"The size of this Series B financing, especially this quickly after our Series A round last year, is an endorsement of the value of our platform and the pace at which we have developed. It allows us to scale our impact with the launch of our Rare Treatment Accelerator programme and to progress into clinical trials."

"We’re delighted to welcome our new corporate and VC investors from Japan and China, as well as having the continued strong support of our existing investors, who together form a world-class group that will help scale CTT quickly to exploit the market opportunity for its technology. CTT has grown rapidly over the last several years, and we’re looking forward to being able to continue executing on our growth plan and sharpening our commercialization focus within the consumer electronics, automotive and industrial markets. The partners we have and the injection of new capital means we can expect to enable our customers to begin rolling out the technology at scale in the near future."

"This funding marks the start of the next phase in Paragraf’s growth. I am extremely proud of the young team at Paragraf who have collectively delivered the early strategy milestones with great skill. This next phase will allow Paragraf to make these truly game-changing technologies a reality. Paragraf is continually seeking like-minded collaborative development, production and commercial partners to accelerate the delivery of the many exciting electronics technology opportunities graphene has to offer."

"This seed funding allows us to accelerate our work at a critical time in the development of quantum computers. Computers are central to the design of many new products, but when we try to model systems at the level of individual atoms, the rules that govern their behaviour are fundamentally different. Even huge supercomputers are limited to approximations. As a result the design of new drugs and materials remains primarily a laboratory, rather than a computational, exercise. Riverlane’s software aims to unleash the huge potential of quantum computers."

"Mobility is changing fast but transport decision-making is slow and expensive, based on poor data. Cities need to accommodate growth, improve resilience and serve an ageing population while improving accessibility, air quality and energy consumption. Operators are facing increasingly low margins and both market and technology disruption, and consumers are expecting an ever more seamless service. This is a large-scale system problem that requires digital transformation to integrate siloed assets and empower effective decision-making."

"This investment is a huge sign of confidence in our efforts to be at the forefront of how enterprises use machines"

"The financial world is being fundamentally changed through Open Banking. It improves our understanding of each individual, allowing us to move away from traditional credit reference agencies."

"Developing sophisticated AI technology while formulating a compelling SaaS proposition is a significant challenge, and it has delayed the real-world deployment of conversational AI for far too long,"

"Cyber-attacks are one of the greatest concerns for the modern business. Organisations’ networks are becoming increasingly complex and accelerated tech adoption creates additional noise for attackers to hide within. Meanwhile, attacker innovation is growing, and their techniques evade current cyber defence tools, which are unable to differentiate between genuinely malicious threats and merely new or unusual activity."

"These are exciting times for Exonar. To receive significant backing from Beringea and Downing Ventures reinforces our belief that the Exonar platform has a significant role to play in enterprise-level data discovery and management. We have a clear vision for future development and the investment will enable us to further enhance our product, enabling our customers to meet current and future data demands such as GDPR and CCPA swiftly, simply and at scale."

"Machine learning is revolutionising every industry. It has become much easier to build predictive models but deploying and managing these models in production is the limiting factor."

"Healx has a simple but profound goal: To transform the lives of rare disease patients. Our technology helps us find treatments where none currently exist,"

"The new Paragraf facility is a significant step towards realising the potential of graphene in commercially viable, scalable electronic devices, bringing the beneficial impacts of this wonder material to the world."

"The conclusion of our Series-E funding is a significant milestone for the business. XMOS is ideally positioned at the crossover between embedded voice processing, biometrics and artificial intelligence, and the funds will enable us to execute our ambitious product development plans. I am particularly delighted to welcome Infineon Technologies as a strategic investor in the business. We have worked closely with the Infineon team on groundbreaking sensor fusion technologies; the investment really strengthens our strategic partnership."